What condition is associated with the use of TCAs for smoking cessation?

The use of tricyclic antidepressants (TCAs) for smoking cessation is particularly associated with bulimia nervosa. This relationship stems from the pharmacological effects of TCAs, which can help manage both depressive symptoms and the particular cravings associated with nicotine addiction. Bulimia nervosa is often characterized by episodes of binge eating and subsequent purging behaviors, as well as significant mood disturbances, which can complicate smoking cessation efforts.

Research suggests that TCAs can be effective in addressing the co-occurring issues of depression and anxiety that may accompany bulimia nervosa, consequently enhancing the likelihood of success in quitting smoking. Meanwhile, while TCAs may have utility in treating a range of mental health disorders, their specific association with smoking cessation in bulimia nervosa sets it apart in this context. Other conditions like post-traumatic stress disorder and chronic anxiety could be treated with different medications or therapies that may not directly link to smoking cessation efforts.